Salim Syed analyst MIZUHO

Currently out of the existing stock ratings of Salim Syed, 174 are a BUY (80.93%), 41 are a HOLD (19.07%).

Salim Syed

Work Performance Price Targets & Ratings Chart

Analyst Salim Syed, currently employed at MIZUHO, carries an average stock price target met ratio of 62.63% that have a potential upside of 46.27% achieved within 334 days.

Salim Syed’s has documented 416 price targets and ratings displayed on 16 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ASMB, Assembly Biosciences at 01-Sep-2026.

Wall Street Analyst Salim Syed

Analyst best performing recommendations are on UBX (UNITY BIOTECHNOLOGY).
The best stock recommendation documented was for UBX (UNITY BIOTECHNOLOGY) at 8/17/2020. The price target of $40 was fulfilled within 1 day with a profit of $1.5 (3.61%) receiving and performance score of 36.14.

Average potential price target upside

AMGN Amgen ASMB Assembly Biosciences BBIO BridgeBio Pharma BIIB Biogen BMY Bristol-Myers Squibb Company CELG Celgene CYTK Cytokinetics GILD Gilead Sciences NKTX Nkarta  UBX Unity Biotechnology WVE Wave Life Sciences Ltd ATRA Atara Biotherapeutics CHRS Coherus BioSciences CRSP Crispr Therapeutics AG PCVX Vaxcyte  ELVN Enliven Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 07-Oct-2024

$400

$22.65 (6.00%)

$400

Buy Since 09-Jan-2024

$450

$72.65 (19.25%)

$450

Hold Since 10-Jan-2025

$435

$57.65 (15.28%)

$400

9 days ago
(04-Sep-2026)

17/18 (94.44%)

$-2.23 (-0.51%)

245

Buy Since 02-Jan-2025

$457

$79.65 (21.11%)

$427

24 days ago
(20-Aug-2026)

11/12 (91.67%)

$23.27 (5.37%)

148

Buy Since 06-Feb-2023

$460

$82.65 (21.90%)

$400

25 days ago
(19-Aug-2026)

2/3 (66.67%)

$17.64 (3.99%)

255

Show more analysts

Please expand the browser size to see the chart

Which stock is Salim Syed most bullish on?

Potential upside of $44.23 has been obtained for CYTK (CYTOKINETICS)

Which stock is Salim Syed most reserved on?

Potential downside of -$25.35 has been obtained for AMGN (AMGEN)

What Year was the first public recommendation made by Salim Syed?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?